Dysthymia Market

Market Overview:

The 7 major dysthymia markets are expected to exhibit a CAGR of 3.7% during 2024-2034.

The dysthymia market has been comprehensively analyzed in IMARC's new report titled "Dysthymia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysthymia, also known as persistent depressive disorder, refers to a chronic form of depression characterized by constant feelings of sadness, low mood, and a lack of interest or pleasure in activities. Various other indications associated with the condition include sleep disturbances, changes in appetite or weight, fatigue, low self-esteem, difficulty concentrating, a sense of being overwhelmed, etc. While the symptoms of dysthymia are generally milder than those of major depressive disorder, they can significantly impact a person's daily life, relationships, and overall well-being. The diagnosis is based on the presence of certain criteria mentioned in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). These criteria include a chronic low mood lasting for at least two years in adults (or one year in children and adolescents), along with various other indications like sleep disturbances, fatigue, feelings of hopelessness, etc. The mental health professional will conduct a detailed assessment, considering the patient's medical and psychological history, family history of mental health conditions, and the impact of symptoms on daily functioning and overall well-being.

The increasing cases of imbalances in various brain chemicals, such as serotonin, dopamine, norepinephrine, etc., that play a crucial role in regulating mood are primarily driving the dysthymia market. In addition to this, the escalating incidences of numerous associated risk factors, including genetic predisposition, traumatic early life experiences, chronic stress, comorbid conditions like anxiety and substance use disorders, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of several anti-depressant medications, such as serotonin-norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors, for managing neurotransmitter imbalances in the brain and reducing depressive indications is further bolstering the market growth. Additionally, the inflating application of light therapy, which involves exposure to bright artificial light to regulate mood and alleviate symptoms of dysthymia, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of mindfulness-based approaches, such as mindfulness-based cognitive therapy (MBCT), since they assist patients in developing greater awareness of their thoughts and emotions while reducing rumination as well as promoting self-compassion, is expected to drive the dysthymia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the dysthymia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dysthymia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysthymia market in any manner.

Key Highlights:

• Dysthymia affects around 105 million individuals worldwide each year, or 1.5% of the population.
• The condition is 38% more prevalent in women (1.8% of women) than in men (1.3% of men).
• The lifetime incidence of dysthymia in community settings tends to range between 3 and 6% in the U.S.
• In primary care settings, the rate is greater, ranging between 5 and 15%.
• Dysthymia affects around 36% of outpatient mental health care patients.
• According to the National Health and Nutrition Examination Survey III (NHANES III), African Americans and Mexican Americans had a higher incidence of dysthymia than Caucasians.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dysthymia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dysthymia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dysthymia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the dysthymia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dysthymia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dysthymia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dysthymia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysthymia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysthymia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dysthymia across the seven major markets?
• What is the size of the dysthymia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dysthymia?
• What will be the growth rate of patients across the seven major markets?
   

Dysthymia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dysthymia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysthymia market?
• What are the key regulatory events related to the dysthymia market?
• What is the structure of clinical trial landscape by status related to the dysthymia market?
• What is the structure of clinical trial landscape by phase related to the dysthymia market?
• What is the structure of clinical trial landscape by route of administration related to the dysthymia market?